120 related articles for article (PubMed ID: 1679529)
1. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
[TBL] [Abstract][Full Text] [Related]
2. Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay.
Sørensen AL; Guldmann-Christensen M; Børgesen M; Petersen RK; Flugt K; Duelund JMH; Kyneb MH; Lorenzen J; Pipó-Ollé E; Epistolio S; Riva A; Dazio G; Merlo E; Meyer T; Christensen UB; Frattini M
PLoS One; 2023; 18(2):e0281558. PubMed ID: 36758042
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Anti-Cancer Activity of
Lim HJ; Byun EH
Prev Nutr Food Sci; 2021 Dec; 26(4):453-458. PubMed ID: 35047442
[No Abstract] [Full Text] [Related]
4. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.
Ritu K; Kumar P; Singh A; Nupur K; Spalgias S; Mrigpuri P; Rajkumar
Mol Biomed; 2021 Dec; 2(1):40. PubMed ID: 34918209
[TBL] [Abstract][Full Text] [Related]
5. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.
Dillon M; Lopez A; Lin E; Sales D; Perets R; Jain P
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680208
[TBL] [Abstract][Full Text] [Related]
6. Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation.
Tan X; Tong L; Li L; Xu J; Xie S; Ji L; Fu J; Liu Q; Shen S; Liu Y; Xiao Y; Gao F; Moses RE; Bardeesy N; Wang Y; Zhang J; Tang L; Li L; Wong KK; Song D; Yang X; Liu J; Li X
Nat Commun; 2021 Aug; 12(1):4853. PubMed ID: 34381046
[TBL] [Abstract][Full Text] [Related]
7. Cadmium-Associated Molecular Signatures in Cancer Cell Models.
Luparello C
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198869
[TBL] [Abstract][Full Text] [Related]
8. Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic K-Ras.
Volonte D; Sedorovitz M; Cespedes VE; Beecher ML; Galbiati F
J Biol Chem; 2021; 296():100242. PubMed ID: 33380422
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Ras mutant causes the hyperactivation of NF-κB via acceleration of its transcriptional activation.
Tago K; Funakoshi-Tago M; Ohta S; Kawata H; Saitoh H; Horie H; Aoki-Ohmura C; Yamauchi J; Tanaka A; Matsugi J; Yanagisawa K
Mol Oncol; 2019 Nov; 13(11):2493-2510. PubMed ID: 31580526
[TBL] [Abstract][Full Text] [Related]
10. Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion.
Choi SY; Kim HW; Jeon SH; Kim BN; Kang N; Yeo CD; Park CK; Kim YK; Lee YH; Lee KY; Lee SH; Park JY; Park MS; Yim HW; Kim SJ
In Vivo; 2019; 33(3):945-954. PubMed ID: 31028221
[TBL] [Abstract][Full Text] [Related]
11. Peroxiredoxins and Beyond; Redox Systems Regulating Lung Physiology and Disease.
Elko EA; Cunniff B; Seward DJ; Chia SB; Aboushousha R; van de Wetering C; van der Velden J; Manuel A; Shukla A; Heintz NH; Anathy V; van der Vliet A; Janssen-Heininger YMW
Antioxid Redox Signal; 2019 Nov; 31(14):1070-1091. PubMed ID: 30799628
[No Abstract] [Full Text] [Related]
12. AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway.
Yang H; Wan Z; Huang C; Yin H; Song D
Lasers Med Sci; 2019 Apr; 34(3):473-478. PubMed ID: 30143925
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
14. [Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].
Shi Y; Lv W; Wang L; Hu J
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):781-786. PubMed ID: 29167009
[TBL] [Abstract][Full Text] [Related]
15. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways.
Naidu S; Shi L; Magee P; Middleton JD; Laganá A; Sahoo S; Leong HS; Galvin M; Frese K; Dive C; Guzzardo V; Fassan M; Garofalo M
Sci Rep; 2017 Nov; 7(1):15441. PubMed ID: 29133857
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring
Yamada T; Amann JM; Tanimoto A; Taniguchi H; Shukuya T; Timmers C; Yano S; Shilo K; Carbone DP
Mol Cancer Ther; 2018 Jan; 17(1):17-25. PubMed ID: 29079711
[TBL] [Abstract][Full Text] [Related]
17. SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.
Riva A; BØrgesen M; Guldmann-Christensen M; Hauge Kyneb M; Voogd K; Andersen C; Epistolio S; Merlo E; Yding Wolff T; Hamilton-Dutoit S; Lorenzen J; Christensen UB; Frattini M
PLoS One; 2017; 12(6):e0178027. PubMed ID: 28636636
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
[TBL] [Abstract][Full Text] [Related]
19. Shining the Light on Senescence Associated LncRNAs.
Ghanam AR; Xu Q; Ke S; Azhar M; Cheng Q; Song X
Aging Dis; 2017 Apr; 8(2):149-161. PubMed ID: 28400982
[TBL] [Abstract][Full Text] [Related]
20. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
